EGFR and non-small cell lung carcinoma: Although EGFR signaling has been implicated in CDDP resistance in various cancer types including non-small cell lung cancer (NSCLC) [17], cervical cancer [18], and OSCC [19], it remains unclear which specific pathway predominantly contributes to the drug resistance in oral cancer.